Nasdaq:US$18.56 (+0.55) | HKEX:HK$29.05 (+0.55) | AIM:£2.92 (+0.08)
Search
Announcements
1
2
345678910111213141516
found Documents: 772
Announcements & Press Releases, Regulatory Notice | 7 Dec 2023

Discloseable Transaction and Connected Transaction in Relation to Disposal of Interest in Consumer Products Businesses
On December 7, 2023, the Seller (a wholly-owned subsidiary of the Company) and HWCL (an indirect subsidiary of CK Hutchison) entered into the Share Sale and Purchase Agreement relating to the disposal by the Seller of its interest in the Consumer Pro
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcement Topics, Announcements & Press Releases, Regulatory Notice | 1 Dec 2023

Monthly Return
HKEX Announcement (PDF)
Announcement Topics, Announcements & Press Releases, Oncology / Immunology | 1 Dec 2023

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
Hong Kong, Shanghai & Florham Park, NJ — Friday, December 1, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today highlights that new clinical data from several ongoing studies with HUTCHMED investigational drug
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcement Topics, Regulatory Notice | 30 Nov 2023

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, November 30, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at November 30, 2023, the issued share capital of HUTCHMED consisted
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Nov 2023

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade — — U.S. approval of FRUZAQLA triggers first milestone payment f
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Nov 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 24 Oct 2023

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, October 24, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 16 Oct 2023

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
Hong Kong, Shanghai & Florham Park, NJ — Monday, October 16, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in com
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Oct 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Sep 2023

Total Voting Rights
Hong Kong, Shanghai, & Florham Park, NJ — Friday, September 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at September 29, 2023, the issued share capital of HUTCHMED consisted
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 29 Sep 2023

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — Hong Kong, Shanghai & Florham Park, NJ — Friday, September 29, 2023: HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUT
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 14 Sep 2023

Director’s Share Dealing
Hong Kong, Shanghai & Florham Park, NJ — Thursday, September 14, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; SEHK:13) has received notifications that the spouse of Mr Graeme Jack, Independent Non-execu
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Sep 2023

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Sep 2023

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, September 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in Chin
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 4 Sep 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 Aug 2023

Total Voting Right
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 29 Aug 2023

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 29, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administrati
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 21 Aug 2023

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China, w
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Interim Reports, Regulatory Notice | 16 Aug 2023

Interim Report 2023
2023 Interim Report (Chinese version)2023 Interim ReportLetter to new registered shareholders and reply form: Election of Language and Means of Receipt of Corporate CommunicationsNotification letter to non-registered shareholders and request form: Notice of Publication of 2023 Interim Report LetterNotification letter to registered shareholders and request form: Notice of Publication of 2023 Interim Report
Announcements & Press Releases, Regulatory Notice | 7 Aug 2023

Next Day Disclosure Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 7 Aug 2023

Exercise of Share Options by a Director
Hong Kong, Shanghai & Florham Park, NJ — Monday, August 7, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has issued a total of 3,000,000 ordinary shares of US$0.10 e
Read More
HKEX Announcement (PDF)
Regulatory Notice | 1 Aug 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Group | 31 Jul 2023

HUTCHMED Reports 2023 Interim Results and Provides Business Updates
Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 20 Jul 2023

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 20, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administratio
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 13 Jul 2023

HUTCHMED Announces Changes to Board of Directors and Technical Committee
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee   Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 13, 2023: HUTCHMED (China) Limit
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcement Topics, Regulatory Notice | 13 Jul 2023

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcement Topics, Oncology / Immunology | 10 Jul 2023

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
Hong Kong, Shanghai & Florham Park, NJ — Monday, July 10, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase I study in China of HMPL-415, an investigational novel selective a
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 3 Jul 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 29 Jun 2023

Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, June 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return: 1. Name of applicant:
Read More
LSE RNS AnnouncementHKEX Announcement
Announcements & Press Releases, Group | 26 Jun 2023

HUTCHMED to Announce 2023 Half-Year Financial Results
Hong Kong, Shanghai & Florham Park, NJ — Monday, June 26, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 16 Jun 2023

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 15 Jun 2023

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
— Application Includes Data from Phase III FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (“BSC”) vs. Placebo plus BSC for Adult Patients with Previously Treated Metastatic Colore
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 9 Jun 2023

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
Hong Kong, Shanghai & Florham Park, NJ — Friday, June 9, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data related to two novel investigational hematological malig
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 6 Jun 2023

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme
Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, June 6, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) announces that on June 5, 2023, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 1 Jun 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 31 May 2023

Total Voting Rights
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 26 May 2023

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO-2 and FRESCO clinical trials —   OSAKA, Japan, CAMBRIDGE, Massachusetts, HONG KONG, SHANGHAI &
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 26 May 2023

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ — Thursday, May 25, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated clinical data related to HUTCHMED’s novel investigational cancer therapi
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 17 May 2023

Standard form for notification of major holdings
TR-1: Standard form for notification of major holding   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i ">1a. Identity of the issuer or the underlying iss
Read More
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 12 May 2023

List of Directors and Their Roles and Functions
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 12 May 2023

Annual General Meeting held on May 12, 2023 – Poll Results
Hong Kong, Shanghai, & Florham Park, NJ: Friday, May 12, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual Genera
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 12 May 2023

HUTCHMED Announces Board of Directors and Board Committee Membership
Hong Kong, Shanghai & Florham Park, NJ  — Friday, May 12, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) refers to its announcement on May 10, 2023 of the appointment of Professor Solange P
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 10 May 2023

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
Hong Kong, Shanghai & Florham Park, NJ  — Wednesday, May 10, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that that Professor Solange Peters is appointed as an Independent
Read More
LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 2 May 2023

Monthly Return
HKEX Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 28 Apr 2023

Total Voting Rights
LSE RNS Announcement (PDF)
Announcements & Press Releases, Regulatory Notice | 21 Apr 2023

Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ — Friday, April 21, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (“LTIP”) on Apr
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 18 Apr 2023

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 18, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its New Drug Application (“NDA”) for fruquintinib in combination with paclitaxe
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Oncology / Immunology | 12 Apr 2023

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, April 12, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that new and updated clinical and non-clinical data related to five HUTCHMED investigation
Read More
LSE RNS Announcement (PDF)HKEX Announcement (PDF)
Announcements & Press Releases, Event, Regulatory Notice | 11 Apr 2023

Annual General Meeting 2023
Date: Friday, May 12, 2023 Time: 5:00 pm Hong Kong Time (10:00 am London Time) Location:1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong  
Read More
Circular - Annual General MeetingForm of ProxyOnline AGM User Guide (PDF)2022 Annual ReportLetter to new registered shareholders and reply formNotification letter to registered holders and request formNotification letter to non-registered holders and request formAnnouncement - Notice of Annual General Meeting2022 Sustainability Report
Announcements & Press Releases, Group | 11 Apr 2023

2022 Annual Report and Notice of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ — Tuesday, April 11, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its 2022 Annual Report together with the Notice of Annual General Meeting and the Form
Read More
HKEX Announcement (PDF)LSE RNS Announcement (PDF)HKEX - Notice of Annual General Meeting
1
2
345678910111213141516